Skip to main content

Published locations for Malignancy risk: Secukinumab shows long-term safety for psoriasis, PsA, ankylosing spondylitis

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Malignancy risk: Secukinumab shows long-term safety for psoriasis, PsA, ankylosing spondylitis

User login

  • Reset your password
  • /content/malignancy-risk-secukinumab-shows-long-term-safety-psoriasis-psa-ankylosing-spondylitis
  • /edermatologynews/article/242444/psoriasis/malignancy-risk-secukinumab-shows-long-term-safety
  • /rheumatologynews/article/242444/psoriasis/malignancy-risk-secukinumab-shows-long-term-safety
  • /oncologypractice/article/242444/psoriasis/malignancy-risk-secukinumab-shows-long-term-safety
  • /hematology-oncology/article/242444/psoriasis/malignancy-risk-secukinumab-shows-long-term-safety
  • /rheumatology/article/242444/psoriasis/malignancy-risk-secukinumab-shows-long-term-safety-psoriasis
  • /dermatology/article/242444/psoriasis/malignancy-risk-secukinumab-shows-long-term-safety-psoriasis
  • /psoriatic-arthritis-icymi/article/242444/psoriasis/malignancy-risk-secukinumab-shows-long-term